Liquidia Corp (LQDA) Stock Price, Quote & News

Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneou...

Industry: Biotechnology

Sector: Healthcare

Phone: 919 328 4400

Fax: 919 328 4402

Website: www.liquidia.com

Address:

419 Davis Drive, Suite 100, Morrisville, United States

eve_t_s_oloccip Jun. 17 at 9:20 PM

$LQDA Who wants to take responsibility for today's price action..... ?????

0 · Reply

stevemano Jun. 17 at 2:51 PM

$LQDA update

1 · Reply

BullRun4 Jun. 16 at 11:08 PM

$LQDA https://finance.yahoo.com/news/one-way-a-prolonged-israel-iran-conflict-could-accelerate-fed-rate-cuts-193755520.html

0 · Reply

EatingCatPoop Jun. 16 at 9:08 PM

$INSM who keeps buying this here when $LQDA just got approved for an arguably better drug for the same market and is valued at barely $1B??

1 · Reply

MarketPro Jun. 16 at 5:41 PM

$LQDA

0 · Reply

EatingCatPoop Jun. 16 at 5:18 PM

$LQDA Way undervalued

1 · Reply

Bornjever Jun. 16 at 3:20 PM

$LQDA so we have earn on August 6 so premarket as they want to showcase a future with increasing and big losses ceasing!!!

0 · Reply

zechariahbailey Jun. 16 at 2:48 PM

$LQDA

0 · Reply

Bornjever Jun. 13 at 6:28 PM

$LQDA just looked at Etrade monthly share rotation and show 400,000 shares purchased by big dogs and zero sold by big dogs that own almost 80 percent of the shares so everything looks very

1 · Reply

ArtVand Jun. 12 at 5:26 PM

$LQDA Check this twitter/X post out. This was a driver behind Wells Fargo's price upgrade referenced below. WF did a survey of pulmonary hypertension specialists. Very compelling - although I will admit that the sample size is small (22). In any event, seems pretty good to this dope (me) https://x.com/sleepingbear84/status/1933172235742609446

1 · Reply

Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD

May 28, 2025, 11:08 AM EDT - 20 days ago

These Analysts Boost Their Forecasts On Liquidia

May 28, 2025, 8:00 AM EDT - 20 days ago

Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference

May 23, 2025, 2:28 PM EDT - 25 days ago

U.S. FDA Approves Liquidia's YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

May 12, 2025, 6:00 AM EDT - 5 weeks ago

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics

May 10, 2025, 9:29 PM EDT - 5 weeks ago

Liquidia Corporation (LQDA) Q1 2025 Earnings Call Transcript

May 8, 2025, 6:30 AM EDT - 5 weeks ago

Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 5, 2025, 4:06 PM EDT - 6 weeks ago

Liquidia Corporation: A Strong Buy On High Likelihood Of FDA Approval This Month

May 2, 2025, 5:28 PM EDT - 6 weeks ago

District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia

May 1, 2025, 8:00 AM EDT - 6 weeks ago

Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 30, 2025, 9:30 AM EDT - 6 weeks ago

Arquitos Capital's Largest Holdings For Q1 2025

Apr 1, 2025, 10:33 AM EDT - 2 months ago

UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 2 months ago

Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 28, 2025, 9:30 AM EDT - 2 months ago

Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder

Mar 19, 2025, 11:56 AM EDT - 3 months ago

Liquidia Corporation (LQDA) Q4 2024 Earnings Call Transcript

Mar 19, 2025, 6:30 AM EDT - 3 months ago

Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 12, 2025, 8:00 AM EDT - 3 months ago

Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025

Nov 15, 2024, 10:20 AM EST - 7 months ago

Liquidia Corporation: Resilience In The Face Of Formidable Opposition Can Pay Off

Nov 13, 2024, 2:40 PM EST - 7 months ago

Liquidia Corporation (LQDA) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 6:30 AM EST - 7 months ago

Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 7, 2024, 10:00 AM EDT - 9 months ago

United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics' Patent

Oct 2, 2024, 6:00 AM EDT - 9 months ago

Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)

Oct 1, 2024, 11:00 AM EDT - 9 months ago

Liquidia Corporation Is Being Sued For Violating Securities Laws And Affected Investors Are Invited To Help The Schall Law Firm

Sep 30, 2024, 11:00 AM EDT - 9 months ago

Liquidia Corporation Is Being Investigated For Violating Securities Laws And Impacted Investors Are Encouraged To Contact The Schall Law Firm

Sep 30, 2024, 8:00 AM EDT - 9 months ago

Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting

Sep 29, 2024, 11:00 AM EDT - 9 months ago

The Schall Law Firm Urges Shareholder Participation In A Securities Fraud Inquiry Into Liquidia Corporation

Sep 28, 2024, 11:00 AM EDT - 9 months ago

Liquidia Corporation Is Being Investigated For Violating Securities Laws And Investors Are Invited To Contact The Schall Law Firm

Sep 24, 2024, 11:00 AM EDT - 9 months ago

Investors Are Invited To Help The Schall Law Firm Investigate Whether Liquidia Corporation Violated Securities Laws

Sep 23, 2024, 11:00 AM EDT - 9 months ago

The Schall Law Firm Is Looking Into Liquidia Corporation For Securities Fraud And Shareholders With Losses Should Reach Out

Sep 21, 2024, 11:00 AM EDT - 9 months ago

Liquidia Corporation May Have Defrauded The Public And The Schall Law Firm Wants Shareholders With Losses To Reach Out

Sep 20, 2024, 11:00 AM EDT - 9 months ago

The Schall Law Firm Has Launched An Inquiry Into Liquidia Corporation For Violating Securities Laws And Affected Investors Should Participate

Sep 19, 2024, 11:00 AM EDT - 9 months ago

Liquidia Corporation Is Being Investigated For Securities Fraud And Shareholders With Losses Are Urged To Reach Out To The Schall Law Firm

Sep 18, 2024, 11:00 AM EDT - 9 months ago

The Schall Law Firm Invites Investors To Join An Inquiry Into Liquidia Corporation For Violating Securities Laws

Sep 17, 2024, 11:00 AM EDT - 9 months ago

Liquidia Corporation Is Being Investigated For Securities Fraud And Affected Stakeholders Are Urged To Reach Out To The Schall Law Firm

Sep 16, 2024, 9:41 AM EDT - 9 months ago

Court Finds United Therapeutics' Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million

Sep 15, 2024, 11:00 AM EDT - 9 months ago

Liquidia Corporation May Have Engaged In Securities Fraud And Investors Are Urged To Join The Schall Law Firm's Investigation

Sep 14, 2024, 11:00 AM EDT - 9 months ago

The Schall Law Firm Is Inquiring Into Liquidia Corporation's Questionable Practices And Shareholders Should Reach Out

Sep 13, 2024, 11:00 AM EDT - 9 months ago

Liquidia Corporation May Have Violated Securities Regulations And The Schall Law Firm Urges Investors To Partake In An Investigation

Sep 12, 2024, 11:00 AM EDT - 9 months ago

The Schall Law Firm Is Looking Into Whether Liquidia Corporation Engaged In Securities Fraud And Affected Shareholders Can Lend A Hand

Sep 11, 2024, 8:26 AM EDT - 9 months ago

Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement

eve_t_s_oloccip Jun. 17 at 9:20 PM

$LQDA Who wants to take responsibility for today's price action..... ?????

0 · Reply

stevemano Jun. 17 at 2:51 PM

$LQDA update

1 · Reply

BullRun4 Jun. 16 at 11:08 PM

$LQDA https://finance.yahoo.com/news/one-way-a-prolonged-israel-iran-conflict-could-accelerate-fed-rate-cuts-193755520.html

0 · Reply

EatingCatPoop Jun. 16 at 9:08 PM

$INSM who keeps buying this here when $LQDA just got approved for an arguably better drug for the same market and is valued at barely $1B??

1 · Reply

MarketPro Jun. 16 at 5:41 PM

$LQDA

0 · Reply

EatingCatPoop Jun. 16 at 5:18 PM

$LQDA Way undervalued

1 · Reply

Bornjever Jun. 16 at 3:20 PM

$LQDA so we have earn on August 6 so premarket as they want to showcase a future with increasing and big losses ceasing!!!

0 · Reply

zechariahbailey Jun. 16 at 2:48 PM

$LQDA

0 · Reply

Bornjever Jun. 13 at 6:28 PM

$LQDA just looked at Etrade monthly share rotation and show 400,000 shares purchased by big dogs and zero sold by big dogs that own almost 80 percent of the shares so everything looks very

1 · Reply

ArtVand Jun. 12 at 5:26 PM

1 · Reply

Randy_Lahey_Trevor_Corey Jun. 12 at 4:26 PM

$NUVB like a rigged carnival game… fucking got burned on $LQDA burned here and burned everywhere else

2 · Reply

JarvisFlow Jun. 12 at 1:09 PM

Wells Fargo has adjusted their stance on Liquidia ( $LQDA ), setting the rating to Overweight with a target price of 23 → 25.

0 · Reply

EatingCatPoop Jun. 12 at 12:13 PM

$LQDA insm dumps 700mm worth of shares on your heads and we have a fully approved and selling drug no raise lmao

0 · Reply

EatingCatPoop Jun. 12 at 12:12 PM

$LQDA Such an incredible opportunity to be at these prices right now. Just wait until they show how much they’ve been selling this quarter.

0 · Reply

speedrr Jun. 12 at 10:56 AM

$LQDA

0 · Reply

Randy_Lahey_Trevor_Corey Jun. 11 at 6:04 PM

$NUVB similar shit happened with $LQDA it rose over time just to get punched in the dick by a drug in phase 2b with positive results.. patience pays until it doesn’t

1 · Reply

ZacksResearch Jun. 11 at 5:20 PM

$INSM skyrocketed 29% after positive phase IIb data! 🚀 🌟 TPIP led to a placebo-adjusted 35% reduction in pulmonary vascular resistance for PAH patients. 📈 Year to date, INSM shares are up 32%, beating the industry’s 1% decline. See why this breakthrough matters for $UTHR and $LQDA here 👉 https://www.zacks.com/commentary/2494541/insmed-stock-jumps-29-on-encouraging-pah-study-results?cid=sm-stocktwits-2-2494541-body&ADID=SYND_STOCKTWITS_TWEET_2_2494541_BODY

1 · Reply